Genetic Testing for Thoracic Aortic Aneurysms/ Dissections and Connective Tissue Related Disorders 2.02.61
This medical policy covers genetic testing for thoracic aortic aneurysms and dissections and related connective tissue disorders. COL3A1 testing for vascular Ehlers-Danlos syndrome may be considered medically necessary in symptomatic individuals with one listed major criterion or two listed minor criteria, FBN1 testing for Marfan syndrome and TGFBR1, TGFBR2, SMAD3, TGFB2 and TGFB3 testing for Loeys-Dietz syndrome have their own listed criteria, and broad multigene panels are considered not medically necessary. The current version is effective September 17, 2026, with an annual review, and the policy intent is unchanged.